Effect of Molecular Weight of PGG–paclitaxel Conjugates on in Vitro and in Vivo Efficacy
Danbo Yang,Xiaoqing Liu,Xinguo Jiang,Yun Liu,Wenbin Ying,Hai Wang,Hao Bai,Wendy D. Taylor,Yuwei Wang,Jean-Pierre Clamme,Erick Co,Padmanabh Chivukula,Kwok Yin Tsang,Yi Jin,Lei Yu
DOI: https://doi.org/10.1016/j.jconrel.2012.04.010
IF: 11.467
2012-01-01
Journal of Controlled Release
Abstract:Polymeric prodrugs are one of the most promising chemotherapeutic agent delivery approaches, displaying unique drug release profiles, serum stability, formulation flexibility, and reduced drug resistance. One of the most important aspects of a polymeric prodrug, albeit a less-extensively studied one, is the polymer's molecular weight, which affects particle formation, drug release and PK/PD profiles, drug stability, and cell uptake; these factors in turn affect the prodrug's maximum tolerated dose and anticancer efficacy. Poly(L-γ-glutamylglutamine) (PGG) is a linear polymer designed to improve the therapeutic index of attached drugs. In this study we selected poly(L-γ-glutamylglutamine)-paclitaxel (PGG–PTX), as a model system for the methodical investigation into the effects of the poly(L-γ-glutamylglutamine) backbone molecular weight on its pharmacological performance. The polymeric prodrug was characterized by NMR, DLS and GPC-MALS, and its anticancer activity in vitro and in vivo was assessed. Herein we present data which provide valuable insight into improving anticancer polymer-based prodrug design and development.